NYSE:AVNS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	791	N/A	N/A	N/A	1
12/31/2026	756	N/A	N/A	N/A	1
12/31/2025	713	N/A	N/A	N/A	3
12/31/2024	685	N/A	N/A	N/A	3
9/30/2024	682	22	37	56	N/A
6/30/2024	682	7	42	62	N/A
3/31/2024	680	-2	13	31	N/A
12/31/2023	673	-10	15	32	N/A
9/30/2023	682	-11	37	53	N/A
6/30/2023	683	9	35	53	N/A
3/31/2023	684	18	64	82	N/A
12/31/2022	684	22	72	91	N/A
9/30/2022	696	23	90	109	N/A
6/30/2022	708	-23	86	104	N/A
3/31/2022	723	10	72	92	N/A
12/31/2021	587	-31	66	87	N/A
9/30/2021	736	-52	15	36	N/A
6/30/2021	738	2	-5	14	N/A
3/31/2021	715	-38	-21	N/A	N/A
12/31/2020	715	-29	-23	-2	N/A
9/30/2020	720	14	-30	-6	N/A
6/30/2020	705	-17	-51	-24	N/A
3/31/2020	714	-22	-100	-57	N/A
12/31/2019	698	-46	-125	-74	N/A
9/30/2019	678	-42	-139	-79	N/A
6/30/2019	671	-27	-194	-130	N/A
3/31/2019	660	-17	-247	-195	N/A
12/31/2018	652	-8	-195	-146	N/A
9/30/2018	649	-1	-118	-74	N/A
6/30/2018	634	-16	N/A	17	N/A
3/31/2018	622	-28	N/A	134	N/A
12/31/2017	612	-32	N/A	144	N/A
9/30/2017	-171	-150	N/A	125	N/A
6/30/2017	76	-130	N/A	152	N/A
3/31/2017	327	-112	N/A	183	N/A
12/31/2016	566	-83	N/A	189	N/A
9/30/2016	1,584	44	N/A	167	N/A
6/30/2016	1,576	-435	N/A	136	N/A
3/31/2016	1,565	-434	N/A	100	N/A
12/31/2015	509	-101	N/A	98	N/A
9/30/2015	1,612	-443	N/A	115	N/A
6/30/2015	1,631	20	N/A	120	N/A
3/31/2015	1,656	7	N/A	162	N/A
12/31/2014	1,672	27	N/A	148	N/A
9/30/2014	1,664	69	N/A	184	N/A
6/30/2014	1,675	125	N/A	222	N/A
3/31/2014	1,677	168	N/A	210	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if AVNS's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if AVNS's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if AVNS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AVNS's revenue (4.6% per year) is forecast to grow slower than the US market (9% per year).

High Growth Revenue: AVNS's revenue (4.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AVNS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 11:39
End of Day Share Price	2025/01/02 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Avanos Medical, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ravi Misra	Berenberg
Kristen Stewart	CL King & Associates, Inc.
Kristen Stewart	Deutsche Bank

Avanos Medical Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 8.5% to US$25.50

Avanos Medical, Inc. Provides Earnings Guidance for the Full Year 2024

Avanos Medical, Inc. Provides Earnings Guidance for the Year 2024

Avanos Medical, Inc. Provides Earnings Guidance for 2024

Price target decreased by 8.9% to US$25.50

Avanos Medical, Inc. Provides Financial Guidance for the Year 2023

Recent updates

What Is Avanos Medical, Inc.'s (NYSE:AVNS) Share Price Doing?

Avanos Medical, Inc. Appoints Warren Machan as Interim Chief Financial Officer

Avanos Medical, Inc. Launches New CORGRIP SR

Third quarter 2024 earnings released: EPS: US$0.13 (vs US$0.19 loss in 3Q 2023)

Avanos Medical, Inc. Announces Chief Executive Officer Changes

Avanos Medical, Inc.'s (NYSE:AVNS) Price Is Right But Growth Is Lacking

Avanos Medical, Inc. to Report Q3, 2024 Results on Oct 30, 2024

There May Be Some Bright Spots In Avanos Medical's (NYSE:AVNS) Earnings

Price target increased by 8.5% to US$25.50

Second quarter 2024 earnings released: EPS: US$0.094 (vs US$0.092 loss in 2Q 2023)

Avanos Medical, Inc. Provides Earnings Guidance for the Full Year 2024

Avanos Medical, Inc. Appoints Indrani Franchini to its Board of Directors

Avanos Medical, Inc. Appoints Sigfrido (Sig) Delgado as Senior Vice President, Integrated Supply Chain

Avanos Medical, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$0.011 (vs US$0.17 loss in 1Q 2023)

Avanos Medical, Inc. to Report Q1, 2024 Results on May 02, 2024

Lacklustre Performance Is Driving Avanos Medical, Inc.'s (NYSE:AVNS) Low P/S

CEO & Director exercised options and sold US$302k worth of stock

Senior VP recently sold US$153k worth of stock

Avanos Medical, Inc., Annual General Meeting, Apr 25, 2024

Avanos Medical, Inc. Announces Voluntary Recall of Mic Gastric - Jejunal Feeding Tube Kits

Avanos Medical, Inc. Provides Earnings Guidance for 2024

Full year 2023 earnings released: US$0.21 loss per share (vs US$1.08 profit in FY 2022)

Avanos Medical, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Is Avanos Medical (NYSE:AVNS) A Risky Investment?

Price target decreased by 8.9% to US$25.50

Investor sentiment improves as stock rises 15%

Avanos Medical, Inc. Provides Financial Guidance for the Year 2023

Price target decreased by 8.6% to US$26.50

Third quarter 2023 earnings released: US$0.19 loss per share (vs US$0.34 profit in 3Q 2022)

Avanos Medical, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Consensus revenue estimates fall by 11%

Some Avanos Medical, Inc. (NYSE:AVNS) Analysts Just Made A Major Cut To Next Year's Estimates

When Should You Buy Avanos Medical, Inc. (NYSE:AVNS)?

New minor risk - Earnings quality

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Avanos Medical, Inc. Provides Earnings Guidance for the Year 2023

Avanos Medical, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Avanos Medical: Leaning Up, Attractive Returns On Incremental Capital, Reiterate Buy

Avanos Medical, Inc.(NYSE:AVNS) dropped from Russell 2000 Dynamic Index

Avanos Medical, Inc. (NYSE:AVNS) entered into a definitive agreement to acquire Diros Technology Inc.

SunMed, LLC entered into a Purchase Agreement to acquire Respiratory Health Business from Avanos Medical, Inc. (NYSE:AVNS) for $110 million.

We Think Avanos Medical (NYSE:AVNS) Can Manage Its Debt With Ease

Avanos Medical, Inc. (NYSE:AVNS) Stocks Pounded By 26% But Not Lagging Market On Growth Or Pricing

Investor sentiment deteriorates as stock falls 21%

Avanos Medical (NYSE:AVNS) Is Looking To Continue Growing Its Returns On Capital

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Avanos Medical (NYSE:AVNS) Using Too Much Debt?

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Avanos Medical Q4 2022 Earnings Preview

Avanos Medical, Inc. Announces Resignation of Arjun R. Sarker as Senior Vice President, Effective May 10, 2023

Avanos Medical, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Avanos Medical, Inc. (NYSE:AVNS) Shares Could Be 30% Below Their Intrinsic Value Estimate

Why Avanos Medical, Inc. (NYSE:AVNS) Could Be Worth Watching

Avanos Medical, Inc. Announces Executive Changes

Insufficient new directors

Avanos Medical, Inc. Appoints Sudhakar Varshney as Senior Vice President, Global Supply Chain & Procurement

Investor sentiment improved over the past week

Price target decreased to US$27.67

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avanos Medical, Inc. Affirms Revenue Guidance for the Full-Year 2022

Avanos Medical reports Q3 mixed earnings; reaffirms FY22 guidance

Avanos Medical, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Avanos Medical, Inc. Announces Resignation of Maria Sainz, Member of the Board of Directors, Effective January 1, 2023

Price target decreased to US$32.33

Avanos: Recent Entry To Hyaluronic Acid Market Sparks Interesting Debate

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Avanos Medical, Inc. Provides Earnings Outlook for the Full Year 2022

Avanos Medical Q2 2022 Earnings Preview